![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0190.jpg)
Conclusions
•
Risk of hematological SMNs has decreased over time
•
Risk solid SMNs does not appear to decrease in
patients treated before 2000, potentially due to
changes in chemotherapy regimens and more breast
cancer screening.
•
Awareness of increased SMN risk remains crucial for
HL survivors.
Schaapveld et al , NEJM 2015